Natalie Sampson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2072682/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer. Cancer Letters, 2022, 530, 156-169.	3.2	49
2	MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors. American Journal of Pathology, 2021, 191, 1094-1107.	1.9	14
3	p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. Endocrine-Related Cancer, 2020, 27, 187-198.	1.6	17
4	NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer. Tumor Biology, 2019, 41, 101042831983000.	0.8	8
5	Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review. Gerontology, 2019, 65, 458-464.	1.4	153
6	Inhibition of Nox4â€dependent ROS signaling attenuates prostate fibroblast activation and abrogates stromalâ€mediated protumorigenic interactions. International Journal of Cancer, 2018, 143, 383-395.	2.3	48
7	Succinate Accumulation Is Associated with a Shift of Mitochondrial Respiratory Control and HIF-1α Upregulation in PTEN Negative Prostate Cancer Cells. International Journal of Molecular Sciences, 2018, 19, 2129.	1.8	15
8	A role for TSPO in mitochondrial Ca2+ homeostasis and redox stress signaling. Cell Death and Disease, 2017, 8, e2896-e2896.	2.7	75
9	Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture. International Journal of Molecular Sciences, 2016, 17, 1458.	1.8	53
10	GPR30 Promotes Prostate Stromal Cell Activation via Suppression of ERα Expression and Its Downstream Signaling Pathway. Endocrinology, 2016, 157, 3023-3035.	1.4	27
11	ROS signaling by NADPH oxidase 5 modulates the proliferation and survival of prostate carcinoma cells. Molecular Carcinogenesis, 2016, 55, 27-39.	1.3	61
12	The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. Cancer Letters, 2015, 367, 113-121.	3.2	46
13	Redox Signaling as a Therapeutic Target to Inhibit Myofibroblast Activation in Degenerative Fibrotic Disease. BioMed Research International, 2014, 2014, 1-14.	0.9	46
14	Re: Delila Gasi Tandefelt, Joost L. Boormans, Hetty A. van der Korput, Guido W. Jenster, Jan Trapman. A 36-gene Signature Predicts Clinical Progression in a Subgroup of ERG-positive Prostate Cancers. Eur Urol 2013;64:941–50. European Urology, 2014, 65, e102-e103.	0.9	4
15	Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055. Phytomedicine, 2013, 20, 1306-1314.	2.3	13
16	Stromal Insulin-Like Growth Factor Binding Protein 3 (IGFBP3) Is Elevated in the Diseased Human Prostate and Promotes ex Vivo Fibroblast-to-Myofibroblast Differentiation. Endocrinology, 2013, 154, 2586-2599.	1.4	29
17	In vitro model systems to study androgen receptor signaling in prostate cancer. Endocrine-Related Cancer, 2013, 20, R49-R64.	1.6	81
18	Dickkopfâ€related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer. Prostate, 2013, 73, 1441-1452.	1.2	26

NATALIE SAMPSON

#	Article	IF	CITATIONS
19	Re-evaluation of the Role of Calcium Homeostasis Endoplasmic Reticulum Protein (CHERP) in Cellular Calcium Signaling. Journal of Biological Chemistry, 2013, 288, 355-367.	1.6	77
20	Phosphodiesterase Type 5 Inhibition Reverts Prostate Fibroblast-to-Myofibroblast Trans-Differentiation. Endocrinology, 2012, 153, 5546-5555.	1.4	28
21	PAGE4 Positivity Is Associated with Attenuated AR Signaling and Predicts Patient Survival in Hormone-Naive Prostate Cancer. American Journal of Pathology, 2012, 181, 1443-1454.	1.9	24
22	Seminal plasma enhances and accelerates progesterone-induced decidualisation of human endometrial stromal cells. Reproduction, Fertility and Development, 2012, 24, 517.	0.1	12
23	Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-15.	1.9	53
24	ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma. Molecular Endocrinology, 2011, 25, 503-515.	3.7	140
25	miRâ€17, miRâ€19b, miRâ€20a, and miRâ€106a are downâ€regulated in human aging. Aging Cell, 2010, 9, 291	295.0	338
26	Identification of evolutionarily conserved genetic regulators of cellular aging. Aging Cell, 2010, 9, 1084-1097.	3.0	57
27	Attenuated Proliferation and Trans-Differentiation of Prostatic Stromal Cells Indicate Suitability of Phosphodiesterase Type 5 Inhibitors for Prevention and Treatment of Benign Prostatic Hyperplasia. Endocrinology, 2010, 151, 3975-3984.	1.4	44
28	Dysregulation of Dkkâ€3 expression in benign and malignant prostatic tissue. Prostate, 2008, 68, 540-547.	1.2	51
29	Human chorionic gonadotropin (hCC) in the male reproductive tract. Molecular and Cellular Endocrinology, 2007, 260-262, 190-196.	1.6	23
30	The ageing male reproductive tract. Journal of Pathology, 2007, 211, 206-218.	2.1	81
31	GAGEC1, a cancer/testis associated antigen family member, is a target of TGF-β1 in age-related prostatic disease. Mechanisms of Ageing and Development, 2007, 128, 64-66.	2.2	9
32	SF4 and SFRS14, two related putative splicing factors on human chromosome 19p13.11. Gene, 2003, 305, 91-100.	1.0	29
33	Comparative genomic sequencing reveals a strikingly similar architecture of a conserved syntenic region on human chromosome 11p15.3 (including gene ST5) and mouse chromosome 7. Cytogenetic and Genome Research, 2001, 93, 284-290.	0.6	18
34	Mutation of the Na-K-Cl Co-Transporter Gene Slc12a2 Results in Deafness in Mice. Human Molecular Genetics, 1999, 8, 1579-1584.	1.4	154